Affiliation:
1. Division of Gastroenterology and Hepatology, Digestive Health Center, Augusta University, Augusta, Georgia, USA;
2. Salix Pharmaceuticals, Bridgewater, New Jersey, USA;
3. Oklahoma Foundation for Digestive Research (retired), Oklahoma City, Oklahoma, USA.
Abstract
INTRODUCTION:
Chronic idiopathic constipation (CIC) is a common condition that affects some patient groups more often. Demographic/clinical characteristics can differ in presentation and therapeutic response. The impact of these characteristics on plecanatide efficacy/safety was examined.
METHODS:
Data from 2 identically designed, randomized, phase 3 trials of adults with CIC receiving 3 mg of plecanatide, 6 mg of plecanatide, or placebo for 12 weeks were analyzed. Subgroups were baseline age, body mass index (BMI), race/ethnicity, and sex/gender. Endpoints included durable overall complete spontaneous bowel movement (CSBM) responder rate, weekly CSBMs and spontaneous bowel movements (SBMs), and adverse events.
RESULTS:
Overall (N = 2,639; 3 mg of plecanatide [n = 877]; 6 mg of plecanatide [n = 877]; and placebo [n = 885]), CSBM responder rates were significantly greater with 3 mg of plecanatide and 6 mg of plecanatide vs placebo in subgroups with those younger than 65 years (P < 0.001), females (P < 0.001), White individuals (P < 0.001), and BMI <25 kg/m2 (P ≤ 0.004) and 25–30 kg/m2 (P < 0.001); as well, for 3 mg: 65 years or older (P = 0.03), non-White individuals (P < 0.001), and BMI ≥30 kg/m2 (P = 0.02). Improvement from baseline in weekly CSBM and SBM frequency occurred in all subgroups for both plecanatide doses vs placebo (P ≤ 0.02) at week 12, except those aged 65 years or older for 6 mg of plecanatide. The most common adverse event was diarrhea (3 mg [4.9%]; 6 mg [5.4%]; and placebo [1.3%]).
DISCUSSION:
Pooled data from identically designed CIC trials strengthened the ability to identify meaningful subgroup comparisons regarding plecanatide efficacy and safety.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference15 articles.
1. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: Systematic review and meta-analysis;Suares;Am J Gastroenterol,2011
2. Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom;Palsson;Gastroenterology,2020
3. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study;Sperber;Gastroenterology,2021
4. The humanistic and economic burden of chronic idiopathic constipation in the USA: A systematic literature review;Nag;Clin Exp Gastroenterol,2020
5. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden;Heidelbaugh;Am J Gastroenterol,2015